Industry news

  1. New study supports FDA's decision to approve Copiktra (duvelisib)

    woman smiling sunny

    Phase III trial shows that Copiktra (duvelisib) may be an option for patients with relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma.

    Read more »
  2. Cancer medicine, Lartruvo (olaratumab), does not prolong life

    old bench

    After failing to show a clear benefit over chemotherapy on its own, both the FDA and EMA do not recommend Lartruvo (olaratumab) for use in combination with chemotherapy for new STS patients.

    Read more »
  3. Onpattro (patisiran): the first RNAi therapeutic approved in the European Union

    Onpattro (patisiran) is a first-in-class treatment that slows down the progression of hereditary transthyretin amyloidosis (hATTR).

    EU approval OK hand gesture

    Read more »
  4. Erleada (apalutamide) gets positive opinion from the EMA

    New medicine shows statistically significant improvements for prostate cancer patients.

    backlit man on mountain arms out

    Read more »
  5. Truxima (rituximab) gains FDA approval as the first biosimilar for Non-Hodgkin's Lymphoma

    A new biosimilar, Truxima (rituximab), shows comparable results to the reference medicine, Rituxan (rituximab), and takes FDA one step further toward expanding patient access to medicines.

    approved stamp with stars

    Read more »
  6. Vyndaqel (tafamidis) prolongs life of FAP patients

    Positive news for patients with early-stage FAP; results from a Portuguese study show that a liver transplant or Vyndaqel may extend survivability.

    grandfather pointing into sea

    Read more »
  7. A new gene therapy on the horizon for SMA

    Zolgensma (onasemnogene abeparvovec-xxxx) to receive priority review by FDA as a one-time treatment of type 1 spinal muscular atrophy (SMA).

    baby outside reaching toward viewer

    Read more »
  8. Alunbrig (brigatinib) approved in Europe for another type of lung cancer

    The European Commission has approved Alunbrig (brigatinib) for the treatment of a specific type of lung cancer.

    eu stars

    Read more »
  9. Ocrevus (ocrelizumab) helps preserve hand and arm function in PPMS

    In an exploratory study Ocrevus (ocrelizumab) slowed down loss of function in the upper extremities for patients with primary progressive multiple sclerosis (PPMS).

    woman raised hands near water

    Read more »
  10. Bavencio (avelumab) misses ovarian cancer trial endpoints

    A late-stage study testing Bavencio (avelumab) has failed to meet its primary endpoints in patients with certain forms of ovarian cancer.

    woman backlit sun field

    Read more »
Posts loader